跳到正文
原文
Nature 健康护理主题·· 2026-10-20AI 评分10

勘误:FcRH5×CD3双特异性抗体cevostamab治疗复发或难治性多发性骨髓瘤的I期试验

Author Correction: FcRH5×CD3 bispecific antibody cevostamab in relapsed or refractory multiple myeloma: a phase 1 trial

AI 导读

Nature Medicine刊发关于FcRH5×CD3双特异性抗体cevostamab治疗复发或难治性多发性骨髓瘤I期试验的勘误声明。该勘误指出,原文扩展数据图3b中两个子图的左侧x轴标签被错误标记为“No 1q gain or amp”,应更正为“1q normal”。此更正已同步更新至该文章的HTML和PDF版本。

正文
  • Author Correction
  • Open access
  • Published: 20 October 2026

Nature Medicine (2026) Cite this article

Correction to: Nature Medicine https://doi.org/10.1038/s41591-026-04522-3, published online 22 July 2026.

In the version of the article initially published, in Extended Data Fig. 3b, the left x-axis label of both panels was “No 1q gain or amp” but should have been “1q normal”. This correction has been made to the HTML and PDF versions of the article.

Author information

Author notes

  1. These authors contributed equally: Adam D. Cohen, Joshua Richter, Suzanne Trudel, Alexander Lesokhin.

Authors and Affiliations

  1. Abramson Cancer Center and University of Pennsylvania, Philadelphia, PA, USA

    Adam D. Cohen

  2. Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA

    Joshua Richter

  3. Princess Margaret Cancer Centre and University of Toronto, Toronto, Ontario, Canada

    Suzanne Trudel

  4. Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA

    Alexander Lesokhin

  5. Dana-Farber Cancer Institute, Boston, MA, USA

    Jacob P. Laubach

  6. The University of Texas MD Anderson Cancer Center, Houston, TX, USA

    Sheeba K. Thomas

  7. Peter MacCallum Cancer Centre, Sir Peter MacCallum Department of Oncology, Melbourne University, and The Royal Melbourne Hospital, Melbourne, Victoria, Australia

    Simon J. Harrison

  8. O’Neal Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL, USA

    Luciano J. Costa

  9. Alfred Health-Monash University, Melbourne, Victoria, Australia

    Andrew Spencer

  10. Mayo Clinic in Arizona, Phoenix, AZ, USA

    Rafael Fonseca

  11. University of Colorado School of Medicine, Aurora, CO, USA

    Peter A. Forsberg

  12. Tennessee Oncology and Sarah Cannon Research Institute, Nashville, TN, USA

    Jesus G. Berdeja

  13. Jewish General Hospital, McGill University, Montreal, Quebec, Canada

    Rayan Kaedbey

  14. Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, Alberta, Canada

    Nizar J. Bahlis

  15. Clínica Universidad de Navarra, Pamplona, Spain

    Paula Rodriguez-Otero

  16. Hospital Universitario de Salamanca, Instituto de Investigación Biomédica de Salamanca (IBSAL), Centro de Investigación del Cáncer (CIC) and Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Salamanca, Spain

    Maria-Victoria Mateos

  17. Genentech, Inc., South San Francisco, CA, USA

    Tulika Tyagi, Divya Samineni, Wenyu Liu, Rin Nakamura, Voleak Choeurng, Chihunt Wong & James Cooper

  18. City of Hope Duarte, Duarte, CA, USA

    Amrita Krishnan

Authors

  1. Adam D. Cohen
  2. Joshua Richter
  3. Suzanne Trudel
  4. Alexander Lesokhin
  5. Jacob P. Laubach
  6. Sheeba K. Thomas
  7. Simon J. Harrison
  8. Luciano J. Costa
  9. Andrew Spencer
  10. Rafael Fonseca
  11. Peter A. Forsberg
  12. Jesus G. Berdeja
  13. Rayan Kaedbey
  14. Nizar J. Bahlis
  15. Paula Rodriguez-Otero
  16. Maria-Victoria Mateos
  17. Tulika Tyagi
  18. Divya Samineni
  19. Wenyu Liu
  20. Rin Nakamura
  21. Voleak Choeurng
  22. Chihunt Wong
  23. James Cooper
  24. Amrita Krishnan

Corresponding author

Correspondence to Adam D. Cohen.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Cohen, A.D., Richter, J., Trudel, S. et al. Author Correction: FcRH5×CD3 bispecific antibody cevostamab in relapsed or refractory multiple myeloma: a phase 1 trial. Nat Med (2026). https://doi.org/10.1038/s41591-026-04757-0

Download citation

  • Published: 20 October 2026

  • Version of record: 20 October 2026

  • DOI: https://doi.org/10.1038/s41591-026-04757-0

来源:Nature 健康护理主题 · nature.com